These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

127 related articles for article (PubMed ID: 24811400)

  • 21. Is a longer time interval between recombinant human deoxyribonuclease (dornase alfa) and chest physiotherapy better? A multi-center, randomized crossover trial.
    Wilson CJ; Robbins LJ; Murphy JM; Chang AB
    Pediatr Pulmonol; 2007 Dec; 42(12):1110-6. PubMed ID: 17955550
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Successful treatment of atelectasis with Dornase alpha in a patient with congenital muscular dystrophy.
    Crescimanno G; Marrone O
    Rev Port Pneumol; 2014; 20(1):42-5. PubMed ID: 24095150
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Sinonasal inhalation of dornase alfa administered by vibrating aerosol to cystic fibrosis patients: a double-blind placebo-controlled cross-over trial.
    Mainz JG; Schien C; Schiller I; Schädlich K; Koitschev A; Koitschev C; Riethmüller J; Graepler-Mainka U; Wiedemann B; Beck JF
    J Cyst Fibros; 2014 Jul; 13(4):461-70. PubMed ID: 24594542
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Impact of Clinical, Unit-Specific Guidelines on Dornase Alfa Use in Critically Ill Pediatric Patients Without Cystic Fibrosis.
    Tester C; Raiff D; Heath T
    Hosp Pharm; 2020 Jun; 55(3):199-203. PubMed ID: 32508358
    [No Abstract]   [Full Text] [Related]  

  • 25. Randomized trial of efficacy and safety of dornase alfa delivered by eRapid nebulizer in cystic fibrosis patients.
    Sawicki GS; Chou W; Raimundo K; Trzaskoma B; Konstan MW
    J Cyst Fibros; 2015 Nov; 14(6):777-83. PubMed ID: 25921451
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Impact of pharmacy services on cystic fibrosis medication adherence.
    Zobell JT; Schwab E; Collingridge DS; Ball C; Nohavec R; Asfour F
    Pediatr Pulmonol; 2017 Aug; 52(8):1006-1012. PubMed ID: 28608652
    [TBL] [Abstract][Full Text] [Related]  

  • 27. The effect of dornase alfa on ventilation inhomogeneity in patients with cystic fibrosis.
    Amin R; Subbarao P; Lou W; Jabar A; Balkovec S; Jensen R; Kerrigan S; Gustafsson P; Ratjen F
    Eur Respir J; 2011 Apr; 37(4):806-12. PubMed ID: 20693248
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Nebulized in-line endotracheal dornase alfa and albuterol administered to mechanically ventilated COVID-19 patients: A case series.
    Weber AG; Chau AS; Egeblad M; Barnes BJ; Janowitz T
    medRxiv; 2020 May; ():. PubMed ID: 32511514
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Pilot study of dornase alfa (Pulmozyme) therapy for acquired ventilator-associated infection in preterm infants.
    Scala M; Hoy D; Bautista M; Palafoutas JJ; Abubakar K
    Pediatr Pulmonol; 2017 Jun; 52(6):787-791. PubMed ID: 28052587
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Effect of dornase alfa on inflammation and lung function: potential role in the early treatment of cystic fibrosis.
    Konstan MW; Ratjen F
    J Cyst Fibros; 2012 Mar; 11(2):78-83. PubMed ID: 22093951
    [TBL] [Abstract][Full Text] [Related]  

  • 31. DNase and atelectasis in non-cystic fibrosis pediatric patients.
    Hendriks T; de Hoog M; Lequin MH; Devos AS; Merkus PJ
    Crit Care; 2005 Aug; 9(4):R351-6. PubMed ID: 16137347
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Use of dornase alfa in pediatric patients without cystic fibrosis.
    Daiya KC; Sierra CM
    Hosp Pract (1995); 2023 Apr; 51(2):89-94. PubMed ID: 36723457
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Adherence to treatment in children and adolescent patients with cystic fibrosis.
    Zindani GN; Streetman DD; Streetman DS; Nasr SZ
    J Adolesc Health; 2006 Jan; 38(1):13-7. PubMed ID: 16387243
    [TBL] [Abstract][Full Text] [Related]  

  • 34. A technical feasibility study of dornase alfa delivery with eFlow® vibrating membrane nebulizers: aerosol characteristics and physicochemical stability.
    Scherer T; Geller DE; Owyang L; Tservistas M; Keller M; Boden N; Kesser KC; Shire SJ
    J Pharm Sci; 2011 Jan; 100(1):98-109. PubMed ID: 20533437
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Resolution of lobe collapse in a child with cystic fibrosis with Mycobacterium abscessus using serial intrabronchial rhDNase.
    Xuereb J; Sammut P; Vella C; Balfour-Lynn IM
    Pediatr Pulmonol; 2022 Jun; 57(6):1549-1551. PubMed ID: 35318832
    [TBL] [Abstract][Full Text] [Related]  

  • 36. The use of dornase alpha for post-operative pulmonary atelectasis after congenital heart surgery.
    Ozturk E; Tanidir IC; Haydin S; Onan IS; Odemis E; Bakir I
    Cardiol Young; 2014 Oct; 24(5):807-12. PubMed ID: 23915544
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Adherence to dornase alfa treatment among commercially insured patients with cystic fibrosis.
    Nasr SZ; Chou W; Villa KF; Chang E; Broder MS
    J Med Econ; 2013; 16(6):801-8. PubMed ID: 23506540
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Does the timing of inhaled dornase alfa matter?
    van der Giessen L
    J Cyst Fibros; 2009 Jun; 8 Suppl 1():S6-9. PubMed ID: 19460684
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Small airway deposition of dornase alfa during exacerbations in cystic fibrosis; a randomized controlled clinical trial.
    Bakker EM; Volpi S; Salonini E; Müllinger B; Kroneberg P; Bakker M; Hop WC; Assael BM; Tiddens HA
    Pediatr Pulmonol; 2014 Feb; 49(2):154-61. PubMed ID: 23913868
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Dornase alfa in the treatment of cystic fibrosis in Europe: a report from the Epidemiologic Registry of Cystic Fibrosis.
    Hodson ME; McKenzie S; Harms HK; Koch C; Mastella G; Navarro J; Strandvik B;
    Pediatr Pulmonol; 2003 Nov; 36(5):427-32. PubMed ID: 14520726
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.